Ayrmid has not obtained the necessary financing to support its unsolicited, nonbinding written proposal to purchase the company, Bluebird said.

The company’s board reiterated its recommendation to instead pursue an offer from SK Capital and Carlyle that’s worth about ...

Bluebird has reaffirmed its support for a proposed acquisition after Ayrmid failed to deliver a binding offer by the extended ...

Bluebird bio (bluebird) has reaffirmed its support for a proposed acquisition by Carlyle and SK Capital after rival bidder Ayrmid failed to deliver a binding offer or secure financing by the ...

Bluebird (Nasdaq: BLUE) said its board unanimously recommended going forward with the acquisition offer from Carlyle and SK ...

A ri­val bid by Ayr­mid for blue­bird bio hasn’t crossed the fin­ish line, the biotech said, af­ter fail­ing to con­firm fi­nanc­ing by a Tues­day dead­line … ...

Bluebird bio announced that despite extending the timeline for Ayrmid to complete due diligence and submit a binding offer, Ayrmid failed to meet these conditions. Mark Vachon, chairman of Bluebird’s ...

The biotech firm reiterated its stance following a period of engagement with Ayrmid Ltd., which failed to present a binding proposal or secure the necessary financing to acquire bluebird. On February ...

--(BUSINESS WIRE)-- bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”) today announced that after three weeks of engagement, including a timeline extension, Ayrmid Ltd ...

Bluebird Bio shares fell as much as 8.28% premarket after confirming that Ayrmid failed to submit a binding proposal to acquire bluebird or secure necessary financing, despite a three-week engagement ...